MedTrace Logo

Serum Uremic Toxins and Histological Findings of the Blood Vessels in Dialysis Patients

NCT00412139 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2010-02-09

No results posted yet for this study

Summary

Patients treated by chronic renal replacement therapy are exposed to cardiovascular problems and suffer from an accelerated and sever atherosclerosis. Classical risk factors for atherosclerosis and cardiovascular diseases (CVD) do not explain the full risk of CVD in the dialysis patients. Additional risk factors are therefore likely to exist. The uremic syndrome is attributed to the progressive retention of a large number of compounds, which under normal conditions are excreted by the healthy kidneys. Uremic toxins such are parathormone (PTH), vitamin D and phosphates, cause development of renal osteodystrophy (ROD), i.e. disordered calcium and phosphate metabolism. Both conditions of hyperparathyroid and adynamic bone disease (ABD) lead to an elevated calcium x phosphate product and increased vascular calcification, which might occur in intimal and medial layer of the vessel wall. It is important to consider these processes separately, as the vascular consequences (occlusion with atheromatosis and vascular stiffening through medial calcification) are different. Moreover, the difference between uremic and non-uremic intimal plaque is not the size but its composition, with markedly increased calcium content. Hence, these observations have an important socio-economic impact because of the increased cardiovascular morbidity and mortality.

The investigators hypothesized that uremic toxins in dialysis patients influence directly and/or indirectly the development of atherosclerosis, vascular calcifications and CVD.

Conditions

  • Chronic Renal Failure

Sponsors & Collaborators

  • Ministry of Science and Education, R. Macedonia

    collaborator UNKNOWN

  • University of Skopje

    lead OTHER

Principal Investigators

  • Goce Spasovski, MD, PhD · Department of Nephrology, University Clinical Center, Vodnjanska 17, 1000 Skopje, R. Macedonia

  • Momir Polenakovic, MD, PhD · Macedonian Academy of Science and Arts

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-11-30
Completion
2010-01-31

Countries

  • North Macedonia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00412139 on ClinicalTrials.gov